NCT06955260View on ClinicalTrials.gov

SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
Congenital Heart Disease
Interventions
DRUG

Empagliflozin 10 mg

Participants will take 10 mg of empagliflozin once daily

OTHER

Placebo

Participants will take 10 mg of placebo once daily

Trial Locations (1)

M5G 2C4

University Health Network, Toronto

Sponsors
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Applied Health Research Centre

OTHER

lead

Subodh Verma

OTHER

NCT06955260 - SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure | Biotech Hunter | Biotech Hunter